Inventor · disambiguated record
Jiyun Chen
Also filed as: CHEN JIYUN
12 granted patents·15 pending applications·70 citations·filing 2003–2024
88Inventor score
Top patents by PatentIndex Score
27 records- 0192US11584756B2Heterocyclic compounds as BET inhibitorsNUVATION BIO INC·Filed 2020·Granted Feb 21, 2023·3 cites·31 claims
- 0290US11826430B2Anti-cancer nuclear hormone receptor-targeting compoundsNUVATION BIO INC·Filed 2020·Granted Nov 28, 2023·2 cites·8 claims
- 0390US11292782B2Diarylhydantoin compounds and methods of use thereofNUVATION BIO INC·Filed 2019·Granted Apr 5, 2022·6 cites·39 claims
- 0490US11034669B2Pyrrole and pyrazole compounds and methods of use thereofNUVATION BIO INC·Filed 2019·Granted Jun 15, 2021·6 cites·16 claims
- 0587US7705182B2Multi-substituted selective androgen receptor modulators and methods of use thereofUNIV TENNESSEE RES FOUNDATION·Filed 2003·Granted Apr 27, 2010·28 cites·23 claims
- 0685US7803970B2Multi-substitued selective androgen receptor modulators and methods of use thereofUNIV TENNESSEE RES FOUNDATION·Filed 2004·Granted Sep 28, 2010·19 cites·74 claims
- 0783US10793561B21,8-naphthyridinone compounds and uses thereofNUVATION BIO INC·Filed 2018·Granted Oct 6, 2020·3 cites·76 claims
- 0880US12208141B2Anti-cancer nuclear hormone receptor-targeting compoundsNUVATION BIO INC·Filed 2023·Granted Jan 28, 2025·0 cites·19 claims
- 0979US11028058B2Heterocyclic compounds as adenosine antagonistsNUVATION BIO INC·Filed 2018·Granted Jun 8, 2021·2 cites·52 claims
- 1078US2025276978A1Heterocyclic compounds as bet inhibitorsNUVATION BIO INC·Filed 2024·Application pending·0 cites
- 1176US11174252B2Heterocyclic compounds as kinase inhibitorsNUVATION BIO INC·Filed 2019·Granted Nov 16, 2021·1 cites·106 claims
- 1273US2023339964A1Heterocyclic compounds as bet inhibitorsNUVATION BIO INC·Filed 2023·Application pending·0 cites
- 1368US12398121B2Anti-cancer nuclear hormone receptor-targeting compoundsNUVATION BIO INC·Filed 2022·Granted Aug 26, 2025·0 cites·12 claims
- 1465US2022213122A1Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitorsNUVATION BIO INC·Filed 2021·Application pending·0 cites
- 1562US11192900B2Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitorsNUVATION BIO INC·Filed 2019·Granted Dec 7, 2021·0 cites·25 claims
- 1661US2022220111A11,8-naphthyridinone compounds and uses thereofNUVATION BIO OPERATING COMPANY INC·Filed 2021·Application pending·0 cites
- 1761US2019375732A1Anti-cancer nuclear hormone receptor-targeting compoundsHUNG DAVID·Filed 2019·Application pending·0 cites
- 1860US2023062022A1Heterocyclic compounds as kinase inhibitorsNUVATION BIO INC·Filed 2021·Application pending·0 cites
- 1959US2021292285A1Heterocyclic compounds as adenosine antagonistsNUVATION BIO INC·Filed 2021·Application pending·0 cites
- 2058US2024132522A1Heterocyclic compounds and methods of use thereof1CBIO INC·Filed 2023·Application pending·0 cites
- 2158US2024132449A1Heterocyclic compounds and methods of use thereof1CBIO INC·Filed 2023·Application pending·0 cites
- 2255US2023023009A1Heterocyclic compounds and methods of use thereofSPARCBIO LLC·Filed 2021·Application pending·0 cites
- 2355US2023026856A1Heterocyclic compounds and methods of use thereofSPARCBIO LLC·Filed 2021·Application pending·0 cites
- 2449US2022347187A1Heterocyclic compounds as kinase inhibitorsNUVATION BIO INC·Filed 2020·Application pending·0 cites
- 2548US2022281859A1Heterocyclic compounds as kinase inhibitorsNUVATION BIO INC·Filed 2020·Application pending·0 cites
- 2645US2004224979A1Treating obesity with selective androgen receptor modulatorsFiled 2003·Application pending·0 cites
- 2745US2011082212A1Multi-substituted selective androgen receptor modulators and methods of use thereofDALTON JAMES T·Filed 2010·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →